Research Analysts Issue Forecasts for Savara FY2029 Earnings

Savara Inc (NASDAQ:SVRA - Free Report) - Equities researchers at HC Wainwright reduced their FY2029 earnings per share (EPS) estimates for Savara in a note issued to investors on Wednesday, May 28th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.08 per share for the year, down from their previous estimate of $0.14. HC Wainwright has a "Neutral" rating and a $2.00 price objective on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12).

Other research analysts have also issued reports about the stock. Evercore ISI dropped their price objective on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research note on Wednesday. Guggenheim restated a "buy" rating and set a $8.00 price objective (down from $9.00) on shares of Savara in a research note on Wednesday. Finally, Wells Fargo & Company dropped their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $7.17.

Savara Stock Up 2.2%

Shares of Savara stock traded up $0.05 during trading hours on Friday, reaching $2.29. The company's stock had a trading volume of 2,115,463 shares, compared to its average volume of 1,423,866. Savara has a one year low of $1.89 and a one year high of $5.11. The company has a market capitalization of $395.80 million, a P/E ratio of -5.33 and a beta of 0.44. The stock's fifty day simple moving average is $2.92 and its two-hundred day simple moving average is $2.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Hedge Funds Weigh In On Savara

Several hedge funds have recently modified their holdings of SVRA. Cibc World Markets Corp bought a new stake in Savara during the fourth quarter worth $33,000. XTX Topco Ltd bought a new stake in Savara during the fourth quarter worth $34,000. Ameriprise Financial Inc. bought a new stake in Savara during the fourth quarter worth $37,000. KLP Kapitalforvaltning AS bought a new stake in shares of Savara during the 4th quarter worth $41,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Savara during the 4th quarter worth $48,000. Institutional investors own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.